How do the AMAROS trial results change practice?
Mené sur 1 425 patientes atteintes d'un cancer primitif du sein de stade T1-2 avec envahissement du ganglion sentinelle (durée médiane de suivi : 6,1 ans), cet essai multicentrique européen évalue, du point de vue de la récidive axillaire à 5 ans, la non infériorité d'une radiothérapie axillaire par rapport à un curage ganglionnaire axillaire
In the EORTC 10981-22023 AMAROS trial, patients with clinical T1—2 N0 primary breast cancer were randomly assigned to axillary radiotherapy or axillary lymph node dissection. Patients received their allocated intervention if they were found to have one or two positive sentinel nodes on sentinel node biopsy. The investigators concluded that, for patients with a positive sentinel lymph node, either modality provides excellent and comparable axillary control; however, since the incidence of lymphoe ...
The Lancet Oncology , résumé, 2013